About Open Innovation

Future drug discovery relies on finding solutions for complex unmet medical needs. PD2 and TargetD2 connect external investigators with Lilly science to find compounds that may become medicines.

Read more in the Open Innovation Drug Discovery Executive Summary

The Science of Open Innovation

Modern drug discovery uses complementary approaches to finding novel therapeutics. While TargetD2 focuses on the interactions with specific biological targets, PD2 queries complex cellular systems.

Getting Started

The Open Innovation Drug Discovery program uses a single, universal Material Transfer Agreement (MTA). All affiliated investigators create individual accounts to manage their submissions.

Evaluating Compounds

The Open Innovation Drug Discovery program uses a confidential, automatic algorithm to select structures for biological screening. A full data report is returned to the investigator after screening.

Partnering in Drug Discovery

Once a compound generates promising results, investigators have the option to reveal the structure to Lilly for review. Findings may lead to a partnership for further studies or collaborative agreement.

“The compound that became an oncology marketed drug would still be in a bottle on my shelf in Princeton if it hadn't been for all the work Lilly put into developing it through some 12 years of testing.”

Prof. Edward C. Taylor

“This program has allowed me to focus on what our company does best, and that is to develop new IP for pre-clinical screening.”

– Daniel R. Caffoe
Chairman and Founder, ImQuest Pharmaceuticals, Inc.